Abstract
Cerebral palsy is a clinical descriptor covering a diverse group of permanent, non-degenerative disorders of motor function. Around one-third of cases have now been shown to have an underlying genetic aetiology, with the genetic landscape overlapping with those of neurodevelopmental disorders including intellectual disability, epilepsy, speech and language disorders and autism. Here we review the current state of genomic testing in cerebral palsy, highlighting the benefits for personalized medicine and the imperative to consider aetiology during clinical diagnosis. With earlier clinical diagnosis now possible, we emphasize the opportunity for comprehensive and early genomic testing as a crucial component of the routine diagnostic work-up in people with cerebral palsy.
Key points
-
Currently, a clinical diagnosis of cerebral palsy (CP) is made on observation of signs and symptoms and does not consider aetiology or pathology.
-
CP encompasses a clinically heterogeneous group of disorders — together referred to as cerebral palsies — with at least one-third of cases having a genetic aetiology.
-
CP has a high degree of genetic overlap with neurodevelopmental disorders, such as intellectual disability, epilepsy and autism, and should itself be considered, at least partly, a genetic neurodevelopmental disorder.
-
The presence of known cerebral palsy risk factors, such as prematurity and growth restriction, and the absence of other comorbid neurodevelopmental phenotypes, including intellectual disability and epilepsy, do not rule out a genetic aetiology.
-
Diagnostic practice has not evolved with the fast-accumulating evidence for a genetic contribution to CP aetiology; the nomenclature for genetic cases and the circumstances under which a genetic diagnosis should negate the CP clinical diagnosis lack consensus.
-
An aetiology-driven diagnosis of CP involving a ‘genotype-first’ approach will bring tangible benefits to individuals with CP through precision medicine and improved clinical management.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Delacy, M. J. & Reid, S. M. Profile of associated impairments at age 5 years in Australia by cerebral palsy subtype and gross motor function classification system level for birth years 1996 to 2005. Dev. Med. Child Neurol. 58 (Suppl. 2), 50–56 (2016).
Mutch, L., Alberman, E., Hagberg, B., Kodama, K. & Perat, M. V. Cerebral palsy epidemiology: where are we now and where are we going? Dev. Med. Child. Neurol. 34, 547–551 (1992).
Novak, I. et al. Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA Pediatr. 171, 897–907 (2017).
Shevell, M. Cerebral palsy to cerebral palsy spectrum disorder: time for a name change? Neurology 92, 233–235 (2018).
Moreno-De-Luca, A., Ledbetter, D. H. & Martin, C. L. Genetic insights into the causes and classification of the cerebral palsies. Lancet Neurol. 11, 283–292 (2012).
Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 512–521 (2017).
Smithers-Sheedy, H. et al. What constitutes cerebral palsy in the twenty-first century? Dev. Med. Child Neurol. 56, 323–328 (2014).
Aravamuthan, B. R. et al. Variability in cerebral palsy diagnosis. Pediatrics 147, e2020010066 (2021).
Pham, R. et al. Definition and diagnosis of cerebral palsy in genetic studies: a systematic review. Dev. Med. Child Neurol. 62, 1024–1030 (2020).
Wilson, Y. A. et al. Common data elements to standardize genomics studies in cerebral palsy. Dev. Med. Child Neurol. 64, 1470–1476 (2022).
Kayumi, S. et al. Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants. Genet. Med. 24, 2351–2366 (2022).
Lee, R. W. et al. A diagnostic approach for cerebral palsy in the genomic era. Neuromol. Med. 16, 821–844 (2014).
Pearson, T. S., Pons, R., Ghaoui, R. & Sue, C. M. Genetic mimics of cerebral palsy. Mov. Disord. 34, 625–636 (2019).
Leach, E. L., Shevell, M., Bowden, K., Stockler-Ipsiroglu, S. & van Karnebeek, C. D. M. Treatable inborn errors of metabolism presenting as cerebral palsy mimics: systematic literature review. Orphanet J. Rare Dis. 9, 197 (2014).
Zouvelou, V. et al. The genetic etiology in cerebral palsy mimics: the results from a Greek tertiary care center. Eur. J. Paediatr. Neurol. 23, 427–437 (2019).
Takezawa, Y. et al. Genomic analysis identifies masqueraders of full-term cerebral palsy. Ann. Clin. Transl. Neurol. 5, 538–551 (2018).
Srivastava, S., Lewis, S. A., Kruer, M. C. & Poduri, A. Underrepresentation of the term cerebral palsy in clinical genetics databases. Am. J. Med. Genet. A 188, 3555–3557 (2022).
te Velde, A. et al. Age of diagnosis, fidelity and acceptability of an early diagnosis clinic for cerebral palsy: a single site implementation study. Brain Sci. 11, 1074 (2021).
Morgan, C. et al. The pooled diagnostic accuracy of neuroimaging, general movements, and neurological examination for diagnosing cerebral palsy early in high-risk infants: a case control study. J. Clin. Med. 8, 1879 (2019).
Bamshad, M. J., Nickerson, D. A. & Chong, J. X. Mendelian gene discovery: fast and furious with no end in sight. Am. J. Hum. Genet. 105, 448–455 (2019).
MacLennan, A. H. et al. Genetic or other causation should not change the clinical diagnosis of cerebral palsy. J. Child. Neurol. 34, 472–476 (2019).
Holborn, M. A. et al. The NESHIE and CP Genetics Resource (NCGR): a database of genes and variants reported in neonatal encephalopathy with suspected hypoxic ischemic encephalopathy (NESHIE) and consequential cerebral palsy (CP). Genomics 114, 110508 (2022).
Oskoui, M. et al. Clinically relevant copy number variations detected in cerebral palsy. Nat. Commun. 6, 7949 (2015).
Parolin Schnekenberg, R. et al. De novo point mutations in patients diagnosed with ataxic cerebral palsy. Brain 138, 1817–1832 (2015).
McMichael, G. et al. Rare copy number variation in cerebral palsy. Eur. J. Hum. Genet. 22, 40–45 (2014).
McMichael, G. et al. Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy. Mol. Psychiatry 20, 176–182 (2015).
Srivastava, S. et al. Clinical whole exome sequencing in child neurology practice. Ann. Neurol. 76, 473–483 (2014).
Moreno-De-Luca, A. et al. Molecular diagnostic yield of exome sequencing in patients with cerebral palsy. J. Am. Med. Assoc. 325, 467–475 (2021).
Srivastava, S. et al. Molecular diagnostic yield of exome sequencing and chromosomal microarray in cerebral palsy: a systematic review and meta-analysis. JAMA Neurol. 79, 1287–1295 (2022).
Gonzalez-Mantilla, P. J. et al. Diagnostic yield of exome sequencing in cerebral palsy and implications for genetic testing guidelines: a systematic review and meta-analysis. JAMA Pediatr. 177, 472–478 (2023).
Jahan, I. et al. Epidemiology of cerebral palsy in low- and middle-income countries: preliminary findings from an international multi-centre cerebral palsy register. Dev. Med. Child. Neurol. 63, 1327–1336 (2021).
Yechieli, M. et al. Diagnostic yield of chromosomal microarray and trio whole exome sequencing in cryptogenic cerebral palsy. J. Med. Genet. 59, 759–767 (2022).
May, H. J. et al. Genetic testing in individuals with cerebral palsy. Dev. Med. Child Neurol. 63, 1448–1455 (2021).
van Eyk, C. L. et al. Yield of clinically reportable genetic variants in unselected cerebral palsy by whole genome sequencing. NPJ Genom. Med. 6, 74 (2021).
Chopra, M. et al. Mendelian etiologies identified with whole exome sequencing in cerebral palsy. Ann. Clin. Transl. Neurol. 9, 193–205 (2022).
Mei, H. et al. Genetic spectrum identified by exome sequencing in a Chinese pediatric cerebral palsy cohort. J. Pediatr. 242, 206–212.e6 (2022).
Solé-Navais, P. et al. Genetic effects on the timing of parturition and links to fetal birth weight. Nat. Genet. 55, 559–567 (2023).
Zhang, G. et al. Genetic associations with gestational duration and spontaneous preterm birth. N. Engl. J. Med. 377, 1156–1167 (2017).
Meler, E., Sisterna, S. & Borrell, A. Genetic syndromes associated with isolated fetal growth restriction. Prenat. Diagn. 40, 432–446 (2020).
Nowakowska, B. A. et al. Genetic background of fetal growth restriction. Int. J. Mol. Sci. 23, 36 (2021).
Martin, A. R. et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat. Genet. 51, 1560–1565 (2019).
Friedman, J. M., van Essen, P. & van Karnebeek, C. D. M. Cerebral palsy and related neuromotor disorders: overview of genetic and genomic studies. Mol. Genet. Metab. 137, 399–419 (2022).
Li, N. et al. In-depth analysis reveals complex molecular aetiology in a cohort of idiopathic cerebral palsy. Brain 145, 119–141 (2022).
Elliott, A. M. & Guimond, C. Genetic counseling considerations in cerebral palsy. Mol. Genet. Metab. 137, 428–435 (2022).
Jin, S. C. et al. Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nat. Genet. 52, 1046–1056 (2020).
van Eyk, C. L. et al. Targeted resequencing identifies genes with recurrent variation in cerebral palsy. NPJ Genom. Med. 4, 27 (2019).
de Vries, L. S. et al. COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage. Ann. Neurol. 65, 12–18 (2009).
Yaramis, A. et al. COL4A1-related autosomal recessive encephalopathy in 2 Turkish children. Neurol. Genet. 6, e392 (2020).
Meuwissen, M. E. C. et al. The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature. Genet. Med. 17, 843–853 (2015).
Guey, S. & Hervé, D. Main features of COL4A1-COL4A2 related cerebral microangiopathies. Cereb. Circ. Cogn. Behav. 3, 100140 (2022).
Zagaglia, S. et al. Neurologic phenotypes associated with COL4A1/2 mutations: expanding the spectrum of disease. Neurology 91, e2078–e2088 (2018).
Mancuso, M. et al. Monogenic cerebral small-vessel diseases: diagnosis and therapy. consensus recommendations of the European Academy of Neurology. Eur. J. Neurol. 27, 909–927 (2020).
Miyake, K. et al. Comparison of genomic and epigenomic expression in monozygotic twins discordant for Rett syndrome. PLoS ONE 8, e66729 (2013).
Trivisano, M. et al. Defining the electroclinical phenotype and outcome of PCDH19-related epilepsy: a multicenter study. Epilepsia 59, 2260–2271 (2018).
Radley, J. A. et al. Deep phenotyping of 14 new patients with IQSEC2 variants, including monozygotic twins of discordant phenotype. Clin. Genet. 95, 496–506 (2019).
Rodgers, J., Calvert, S., Shoubridge, C. & McGaughran, J. A novel ARX loss of function variant in female monozygotic twins is associated with chorea. Eur. J. Med. Genet. 64, 104315 (2021).
Fang, H., Deng, X. & Disteche, C. M. X-factors in human disease: impact of gene content and dosage regulation. Hum. Mol. Genet. 30, R285–R295 (2021).
Migeon, B. R. X-linked diseases: susceptible females. Genet. Med. 22, 1156–1174 (2020).
Gecz, J. & Thomas, P. Q. Disentangling the paradox of the PCDH19 clustering epilepsy, a disorder of cellular mosaics. Curr. Opin. Genet. Dev. 65, 169–175 (2020).
Hu, L. et al. A child with a novel DDX3X variant mimicking cerebral palsy: a case report. J. Pediatr. 46, 88 (2020).
Ding, Y. X. & Cui, H. Integrated analysis of genome-wide DNA methylation and gene expression data provide a regulatory network in intrauterine growth restriction. Life Sci. 179, 60–65 (2017).
Tan, Q. et al. Epigenetic signature of preterm birth in adult twins. Clin. Epigenetics 10, 87 (2018).
Sparrow, S. et al. Epigenomic profiling of preterm infants reveals DNA methylation differences at sites associated with neural function. Transl. Psychiatry 6, e716 (2016).
van Dongen, J. et al. Identical twins carry a persistent epigenetic signature of early genome programming. Nat. Commun. 12, 5618 (2021).
Batie, M. et al. Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science 363, 1222–1226 (2019).
Chakraborty, A. A. et al. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science 363, 1217–1222 (2019).
Aref-Eshghi, E. et al. Genomic DNA methylation signatures enable concurrent diagnosis and clinical genetic variant classification in neurodevelopmental syndromes. Am. J. Hum. Genet. 102, 156–174 (2018).
Sadikovic, B., Aref-Eshghi, E., Levy, M. A. & Rodenhiser, D. DNA methylation signatures in mendelian developmental disorders as a diagnostic bridge between genotype and phenotype. Epigenomics 11, 563–575 (2019).
Levy, M. A. et al. Novel diagnostic DNA methylation episignatures expand and refine the epigenetic landscapes of Mendelian disorders. HGG Adv. 3, 100075 (2022).
Garg, P. & Sharp, A. J. Screening for rare epigenetic variations in autism and schizophrenia. Hum. Mutat. 40, 952–961 (2019).
Garg, P. et al. A survey of rare epigenetic variation in 23,116 human genomes identifies disease-relevant epivariations and CGG expansions. Am. J. Hum. Genet. 107, 654–669 (2020).
Al Zahrani, H. et al. Genomics in cerebral palsy phenotype across the lifespan: comparison of diagnostic yield between children and adult population. Mol. Genet. Metab. 137, 420–427 (2021).
Segel, R. et al. Copy number variations in cryptogenic cerebral palsy. Neurology 84, 1660–1668 (2015).
Matthews, A. M. et al. Atypical cerebral palsy: genomics analysis enables precision medicine. Genet. Med. 21, 1621–1628 (2019).
Zech, M. et al. Monogenic variants in dystonia: an exome-wide sequencing study. Lancet Neurol. 19, 908–918 (2020).
Rosello, M. et al. Hidden etiology of cerebral palsy: genetic and clinical heterogeneity and efficient diagnosis by next-generation sequencing. Pediatr. Res. 90, 284–288 (2021).
Suchowersky, O. et al. Hereditary spastic paraplegia initially diagnosed as cerebral palsy. Clin. Park. Relat. Disord. 5, 100114 (2021).
Dalpozzo, F. et al. Infancy onset hereditary spastic paraplegia associated with a novel atlastin mutation. Neurology 61, 580–581 (2003).
Andersen, E. W., Leventer, R. J., Reddihough, D. S., Davis, M. R. & Ryan, M. M. Cerebral palsy is not a diagnosis: a case report of a novel atlastin-1 mutation. J. Paediatr. Child. Health 52, 669–671 (2016).
Rainier, S., Sher, C., Reish, O., Thomas, D. & Fink, J. K. De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. Arch. Neurol. 63, 445–447 (2006).
Yonekawa, T. et al. Extremely severe complicated spastic paraplegia 3A with neonatal onset. Pediatr. Neurol. 51, 726–729 (2014).
Le Roux, M. et al. CACNA1A-associated epilepsy: electroclinical findings and treatment response on seizures in 18 patients. Eur. J. Paediatr. Neurol. 33, 75–85 (2021).
Lazo, P. A. et al. Novel dominant KCNQ2 exon 7 partial in-frame duplication in a complex epileptic and neurodevelopmental delay syndrome. Int. J. Mol. Sci. 21, 444721 (2020).
Weckhuysen, S. et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann. Neurol. 71, 15–25 (2012).
Navratil, M. et al. Ataxia-telangiectasia presenting as cerebral palsy and recurrent wheezing: a case report. Am. J. Case Rep. 16, 631–636 (2015).
Petley, E., Yule, A., Alexander, S., Ojha, S. & Whitehouse, W. P. The natural history of ataxia-telangiectasia (A-T): a systematic review. PLoS ONE 17, e0264177 (2022).
Ou, Y. et al. A de novo loss-of-function mutation in PAFAH1B1 identified in a single case with agyria–pachygyria complex. J. Pediatr. Neurol. 18, 33–38 (2020).
Saillour, Y. et al. LIS1-related isolated lissencephaly: spectrum of mutations and relationships with malformation severity. Arch. Neurol. 66, 1007–1015 (2009).
Shah, S. et al. Childhood presentation of COL4A1 mutations. Dev. Med. Child Neurol. 54, 569–574 (2012).
Kinoshita, K. et al. De novo p.G696S mutation in COL4A1 causes intracranial calcification and late-onset cerebral hemorrhage: a case report and review of the literature. Eur. J. Med. Genet. 63, 103825 (2020).
Boyce, D., McGee, S., Shank, L., Pathak, S. & Gould, D. Epilepsy and related challenges in children with COL4A1 and COL4A2 mutations: a Gould syndrome patient registry. Epilepsy Behav. 125, 108365 (2021).
Nejabat, M. et al. Genetic testing in various neurodevelopmental disorders which manifest as cerebral palsy: a case study from Iran. Front. Pediatr. 9, 734946 (2021).
Friedman, J. et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann. Neurol. 71, 520–530 (2012).
Waak, M. et al. GNAO1-related movement disorder with life-threatening exacerbations: movement phenomenology and response to DBS. J. Neurol. Neurosurg. Psychiatry 89, 221–222 (2018).
Malaquias, M. J. et al. GNAO1 mutation presenting as dyskinetic cerebral palsy. Neurol. Sci. 40, 2213–2216 (2019).
Mountford, H. S., Braden, R., Newbury, D. F. & Morgan, A. T. The genetic and molecular basis of developmental language disorder: a review. Children 9, 586 (2022).
Tan, Y., Liu, D., Gong, J., Liu, J. & Huo, J. The role of F-box only protein 31 in cancer. Oncol. Lett. 15, 4047–4052 (2018).
Dzinovic, I. et al. Variant recurrence confirms the existence of a FBXO31-related spastic-dystonic cerebral palsy syndrome. Ann. Clin. Transl. Neurol. 8, 951–955 (2021).
Mir, A. et al. Truncation of the E3 ubiquitin ligase component FBXO31 causes non-syndromic autosomal recessive intellectual disability in a Pakistani family. Hum. Genet. 133, 975–984 (2014).
Stephenson, S. E. M. et al. Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome. Am. J. Hum. Genet. 109, 601–617 (2022).
Piard, J. et al. The phenotypic spectrum of WWOX-related disorders: 20 additional cases of WOREE syndrome and review of the literature. Genet. Med. 21, 1308–1318 (2019).
Cummings, K., Watkins, A., Jones, C., Dias, R. & Welham, A. Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics. J. Neurodev. Disord. 14, 1 (2022).
Reijnders, M. R. F. et al. De novo loss-of-function mutations in USP9X cause a female-specific recognizable syndrome with developmental delay and congenital malformations. Am. J. Hum. Genet. 98, 373–381 (2016).
Johnson, B. V. et al. Partial loss of USP9X function leads to a male neurodevelopmental and behavioral disorder converging on transforming growth factor β signaling. Biol. Psychiatry 87, 100–112 (2020).
Johnson-Kerner, B. et al. DDX3X-Related Neurodevelopmental Disorder https://www.ncbi.nlm.nih.gov/books/NBK561282/ (GeneReviews, 2020).
Jaglin, X. H. & Chelly, J. Tubulin-related cortical dysgeneses: microtubule dysfunction underlying neuronal migration defects. Trends Genet. 25, 555–566 (2009).
Fourel, G. & Boscheron, C. Tubulin mutations in neurodevelopmental disorders as a tool to decipher microtubule function. FEBS Lett. 594, 3409–3438 (2020).
Fallah, M. S., Szarics, D., Robson, C. M. & Eubanks, J. H. Impaired regulation of histone methylation and acetylation underlies specific neurodevelopmental disorders. Front. Genet. 11, 613098 (2020).
Park, J., Lee, K., Kim, K. & Yi, S. J. The role of histone modifications: from neurodevelopment to neurodiseases. Signal. Transduct. Target. Ther. 7, 217 (2022).
Ronan, J. L., Wu, W. & Crabtree, G. R. From neural development to cognition: unexpected roles for chromatin. Nat. Rev. Genet. 14, 347–359 (2013).
Parenti, I., Rabaneda, L. G., Schoen, H. & Novarino, G. Neurodevelopmental disorders: from genetics to functional pathways. Trends Neurosci. 43, 608–621 (2020).
Fancy, S. P. J. et al. Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer. Nat. Neurosci. 17, 506–512 (2014).
Richard, E. M. et al. Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss. Am. J. Hum. Genet. 108, 2006–2016 (2021).
Saida, K. et al. Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: a study in 42 affected individuals. Genet. Med. 25, 90–102 (2023).
Calame, D. G. et al. Biallelic loss-of-function variants in the splicing regulator NSRP1 cause a severe neurodevelopmental disorder with spastic cerebral palsy and epilepsy. Genet. Med. 23, 2455–2460 (2021).
Kurolap, A. et al. Bi-allelic variants in neuronal cell adhesion molecule cause a neurodevelopmental disorder characterized by developmental delay, hypotonia, neuropathy/spasticity. Am. J. Hum. Genet. 109, 518–532 (2022).
MacLennan, A. H. et al. Cerebral palsy and genomics: an international consortium. Dev. Med. Child. Neurol. 60, 209–210 (2018).
van Eyk, C. L. et al. Analysis of 182 cerebral palsy transcriptomes points to dysregulation of trophic signalling pathways and overlap with autism. Transl. Psychiatry 8, 88 (2018).
International League Against Epilepsy Consortium on Complex Epilepsies. Berkovic S. F., Cavalleri G. L., Koeleman B. P. Genome-wide meta-analysis of over 29,000 people with epilepsy reveals 26 loci and subtype-specific genetic architecture. Preprint at medRxiv https://doi.org/10.1101/2022.06.08.22276120 (2022).
Grove, J. et al. Identification of common genetic risk variants for autism spectrum disorder. Nat. Genet. 51, 431–444 (2019).
Novak, I. et al. State of the Evidence Traffic Lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr. Neurol. Neurosci. Rep. 20, 3 (2020).
Heijtz, R. D., Almeida, R., Eliasson, A. C. & Forssberg, H. Genetic variation in the dopamine system influences intervention outcome in children with cerebral palsy. EBioMedicine 28, 162–167 (2018).
Bagrowski, B. et al. Assessment of the relationship between Val66Met BDNF polymorphism and the effectiveness of gait rehabilitation in children and adolescents with cerebral palsy. Acta Neurobiol. Exp. 82, 1–11 (2022).
Horvath, G. A. et al. Gain-of-function KCNJ6 mutation in a severe hyperkinetic movement disorder phenotype. Neurosci 384, 152–164 (2018).
Sun, J. M. & Kurtzberg, J. Stem cell therapies in cerebral palsy and autism spectrum disorder. Dev. Med. Child. Neurol. 63, 503–510 (2021).
Tai, C. H. et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol. Ther. 30, 509–518 (2022).
Himmelreich, N. et al. Spectrum of DDC variants causing aromatic l-amino acid decarboxylase (AADC) deficiency and pathogenicity interpretation using ACMG-AMP/ACGS recommendations. Mol. Genet. Metab. 137, 359–381 (2022).
Gillespie, M. et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687–D692 (2022).
Wilson, Y. A. et al. People with cerebral palsy and their family’s preferences about genomics research. Public. Health Genom. 25, 22–31 (2022).
Vissers, L. E. L. M., Gilissen, C. & Veltman, J. A. Genetic studies in intellectual disability and related disorders. Nat. Rev. Genet. 17, 9–18 (2016).
Kochinke, K. et al. Systematic phenomics analysis deconvolutes genes mutated in intellectual disability into biologically coherent modules. Am. J. Hum. Genet. 98, 149–164 (2016).
Ge, S. X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36, 2628–2629 (2019).
Oliver, K. L. et al. Genes4Epilepsy: an epilepsy gene resource. Epilepsia 64, 1368–1375 (2023).
Robinson, P. N. et al. The human phenotype ontology: a tool for annotating and analyzing human hereditary disease. Am. J. Hum. Genet. 83, 610–615 (2008).
Köhler, S. et al. The human phenotype ontology in 2021. Nucleic Acids Res. 49, D1207–D1217 (2021).
Lewis-Smith, D. et al. Computational analysis of neurodevelopmental phenotypes: harmonization empowers clinical discovery. Hum. Mutat. 43, 1642–1658 (2022).
Acknowledgements
The authors thank T. Kroes and D. Fornarino for their assistance with the initial curation of cerebral palsy gene lists. J.G. is supported by NHMRC Senior Research Fellowship ID1155224 and C.L.v.E. is supported by The Hospital Research Foundation Fellowship C-MCF-48-2019.
Author information
Authors and Affiliations
Contributions
C.L.v.E. and J.G. contributed equally to discussions of the article content. C.L.v.E. researched and drafted the article. All authors reviewed, edited and approved the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Neurology thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
Human Phenotype Ontology: https://hpo.jax.org/app/
International Cerebral Palsy Genomics Consortium CP Commons data portal: https://icpgc.org/accessing-the-data/
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
van Eyk, C.L., Fahey, M.C. & Gecz, J. Redefining cerebral palsies as a diverse group of neurodevelopmental disorders with genetic aetiology. Nat Rev Neurol 19, 542–555 (2023). https://doi.org/10.1038/s41582-023-00847-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-023-00847-6